微调三号方联合卡瑞利珠单抗治疗晚期食管癌的临床疗效分析OA
Clinical Efficacy of Traditional Chinese Medicine Formula WD3 Combined with Carrilizumab in the Treatment of Advanced Esophageal Cancer
目的:分析中药方剂微调三号方联合卡瑞利珠单抗治疗晚期食管癌的临床疗效.方法:选择江阴市中医院2022 年9 月—2024 年8 月收诊的晚期食管癌患者86 例,采用随机数字表法将其分为观察组(43 例,采用微调三号方联合卡瑞利珠单抗治疗)和对照组(43 例,采用卡瑞利珠单抗治疗).对比两组中医证候评分、生活质量、临床疗效、肿瘤标志物、免疫功能、不良反应及预后.结果:治疗后,两组中医证候评分均降低(P<0.05),观察组治疗后更低(P<0.01);治疗后,两组欧洲癌症病人生活质量测定量表核心量表(QLQ-C30)评分均升高(P<0.05),观察组治疗后更高(P<0.01).观察组客观缓解率、疾病控制率较对照组高(P<0.05,P<0.01).治疗后,两组血清细胞角质蛋白19 片段抗原21-1(CY-FRA21-1)、糖类抗原199(CA199)、鳞状细胞癌相关抗原(SCC-Ag)水平均降低(P<0.05),观察组治疗后更低(P<0.01).治疗后,两组CD4+/CD8+、CD4+、CD3+水平均升高(P<0.05),观察组治疗后更高(P<0.01).两组血小板减少症、皮疹、肝功能损伤、胃肠道反应等Ⅰ~Ⅳ级不良反应总发生率对比差异无统计学意义(P>0.05).随访1 年,观察组失访1 例,对照组失访2 例,随访率为96.51%(83/86),观察组生存率为 83.33%(35/42),对照组生存率为 63.41%(26/41).观察组生存曲线优于对照组(P<0.05).结论:晚期食管癌患者采用微调三号方联合卡瑞利珠单抗治疗效果显著,可改善患者生活质量及免疫功能,降低肿瘤标志物水平,安全可靠,且可延长患者生存时间.
Objective:To analyze the clinical efficacy of the traditional Chinese medicine formula WD3(WD3)combined with carrilizumab in the treatment of advanced esophageal cancer.Methods:A total of 86 patients with advanced esophageal cancer admitted to the Jiangyin Hospital of Traditional Chinese Medicine from September 2022 to August 2024 were divided into observation group(43 cases,WD3 combined with carrilizumab were used for treatment)and control group(43 cases,carrilizumab was used for treatment)by random number table method.TCM symptom score,quality of life,clinical efficacy,tumor markers,immune function,adverse reactions and prognosis were compared between the two groups.Results:After treatment,the scores of TCM symptoms in 2 groups were decreased(P<0.05),and the scores in observation group were lower(P<0.05).After treatment,the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30(QLQ-C30)score was increased in both groups(P<0.05),and higher in observation group(P<0.05).The objective remission rate and disease control rate of observation group were higher than control group(P<0.05).After treatment,the levels of keratin19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen 199(CA199)and squamous cell carcinoma associated antigen(SCC-Ag)in serum of 2 groups were decreased(P<0.05),and the levels were lower in observation group(P<0.05).After treatment,the levels of CD4+/CD8+,CD4+and CD3+were increased in 2 groups(P<0.05),and higher in observation group(P<0.05).There were no significant differences in the total incidence of class I to Ⅳ adverse reactions such as thrombocytopenia,rash,liver function injury and gastrointestinal reactions between the two groups(P>0.05).After one yearoffollow-up,there were1 case lostto follow-upinthe observationgroupand2 caseslost to follow-up in the control group,resulting in a follow-up rate of 96.51%(83/86),and the survival rate was 83.33%(35/42)in the observation group and 63.41%(26/41)in the control group.The survival curve of observation group was better than control group(P<0.05).Conclusion:In patients with advanced esophageal cancer,the combination of WD3 and carrellizumab has significant therapeutic effect,which can improve the quality of life and immune function of patients,reduce the level of tumor markers,is safe and reliable,and can prolong the survival time of patients.
张乐裕;徐小雨;赵国珍
江阴市中医院肿瘤科,江苏 无锡 214400江阴市中医院肿瘤科,江苏 无锡 214400江阴市中医院肿瘤科,江苏 无锡 214400
医药卫生
微调三号方卡瑞利珠单抗食管癌免疫功能肿瘤标志物
WD3CarrilizumabEsophageal cancerImmune functionTumor markers
《中医药学报》 2026 (3)
84-89,6
江阴市卫生健康委员会科研项目(Q202213)
评论